Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886065 · ClinicalTrials.gov registry record · Phase 1
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
A Phase 1 study of Smoldering Multiple Myeloma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 6
- Study locations
NCT02886065: Active Phase 1 study of Smoldering Multiple Myeloma, sponsored by Massachusetts General Hospital.
NCT02886065 is a Phase 1 study of Smoldering Multiple Myeloma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 19 participants, below the 799-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02886065, a Phase 1 study of Smoldering Multiple Myeloma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
Primary Outcome
The proportion of participants who experience dose limiting toxicities and other toxicities. The CTCAE version 4 criteria will be used to grade adverse events.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Hiltonol
- BIOLOGICAL PVX-410
- DRUG Citarinostat
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Weill Cornell Medical College - New York
North Carolina
- Duke University Medical Center - Durham
Ohio
- University Hospital of Cleveland- Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 1 |
What the registry record for NCT02886065 still lists
NCT02886065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 799-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Lenalidomide is the first listed.
NCT02886065 lists 6 locations in 4 states (Massachusetts, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02886065 about?
NCT02886065 is a clinical study titled "A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM". This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
What is the current status of trial NCT02886065?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2017-03-07. Estimated completion is 2026-09-15.
What conditions does trial NCT02886065 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT02886065?
The interventions under investigation include: Lenalidomide (DRUG), Hiltonol (DRUG), PVX-410 (BIOLOGICAL), Citarinostat (DRUG).
Who is sponsoring clinical trial NCT02886065?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02886065 being conducted?
This trial has 6 study locations across Massachusetts, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02886065's enrollment target sits among peer trials
19 20th of 20 higher than 1 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
RECRUITING
-
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RECRUITING
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI